TapewireFind a company

person · Reporting owner

MOLL FREDERIC H

Disclosed activity across 8 companies

Tapewire entity
17739
SEC CIK
0001260157

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BIOLASE, INCBIOL · Entity 11470DirectorJune 30, 2017July 03, 2017
INTUITIVE SURGICAL INCISRG · Entity 2878DirectorSeptember 10, 2003September 12, 2003
Intersect ENT, Inc.XENT · Entity 127294DirectorJanuary 19, 2021February 05, 2021
Lux Health Tech Acquisition Corp.LUXA · Entity 145615DirectorOctober 26, 2020October 26, 2020
PROCEPT BioRobotics CorpPRCT · Entity 4831DirectorJune 09, 2026June 10, 2026
SS Innovations International, Inc.SSII · Entity 5246Director · 10% ownerMarch 06, 2026March 10, 2026
Venus Concept Inc.VERO · Entity 55304DirectorNovember 07, 2019November 08, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIOLASE, INC

Report date June 30, 2017 · Filed July 03, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect251,317 Reported balance After 2017-06-30 transaction · row 1
1 source row

Row 1 · 2017-06-30 · Conversion · Acquired 192,100 · Balance 251,317

F1: On June 30, 2017, as a result of receipt of the Requisite Stockholder Approval (defined and described further in the Securities Purchase Agreement dated April 11, 2017 and filed as Exhibit 99.1 to the Current Report on Form 8-K filed by the Issuer on April 14, 2017), each share of Preferred Stock (as defined below) automatically converted into 100 shares of Common Stock, reflecting a conversion price equal to $1.24 per share.

Series D Participating Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.24Direct0 Reported balance After 2017-06-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2017-06-30 · Conversion · Disposed 1,921 · Balance 0

F2: These shares of Series D Participating Convertible Preferred Stock ("Preferred Stock") were acquired by Frederic H. Moll in a private placement with the Issuer, which closed on April 18, 2017.

F3: The Preferred Stock had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: On June 30, 2017, as a result of receipt of the Requisite Stockholder Approval (defined and described further in the Securities Purchase Agreement dated April 11, 2017 and filed as Exhibit 99.1 to the Current Report on Form 8-K filed by the Issuer on April 14, 2017), each share of Preferred Stock (as defined below) automatically converted into 100 shares of Common Stock, reflecting a conversion price equal to $1.24 per share.

F2: These shares of Series D Participating Convertible Preferred Stock ("Preferred Stock") were acquired by Frederic H. Moll in a private placement with the Issuer, which closed on April 18, 2017.

F3: The Preferred Stock had no expiration date.

INTUITIVE SURGICAL INC

Report date September 10, 2003 · Filed September 12, 2003

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect657,799 Ending reported balance After 2003-09-10 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2003-09-10 · Sale · Disposed 5,000 · Balance 662,799

Row 2 · 2003-09-10 · Sale · Disposed 5,000 · Balance 657,799

Intersect ENT, Inc.

Report date January 19, 2021 · Filed February 05, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect260,961 Reported balance After 2021-01-19 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2021-01-19 · Exercise / conversion · Acquired 12,500 · Balance 260,961

F1: Includes 5,011 restricted stock units.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2021-01-31Direct0 Reported balance After 2021-01-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2021-01-19 · Exercise / conversion · Disposed 12,500 · Balance 0

F2: The vesting commencement date of the option is February 1, 2011. 7500 shares subject to the option vested on February 2, 2011 and 1/60th of the shares subject to the option vested monthly thereafter over 24 months.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 5,011 restricted stock units.

F2: The vesting commencement date of the option is February 1, 2011. 7500 shares subject to the option vested on February 2, 2011 and 1/60th of the shares subject to the option vested monthly thereafter over 24 months.

Lux Health Tech Acquisition Corp.

Report date October 26, 2020 · Filed October 26, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class B Common StockSEC Table II · derivative / convertible securityDirectNot disclosed Reported balance Holding disclosure · report date 2020-10-26 · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · Balance Not disclosed

F1: The Class B common stock will automatically convert into shares of Class A common stock at the completion of the Issuer's initial business combination on a one-for-one basis, subject to adjustment.

Filing footnotes · ownership attribution and instrument terms

F1: The Class B common stock will automatically convert into shares of Class A common stock at the completion of the Issuer's initial business combination on a one-for-one basis, subject to adjustment.

PROCEPT BioRobotics Corp

Report date June 09, 2026 · Filed June 10, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect866,474 Reported balance After 2026-06-09 transaction · row 1
1 source row

Row 1 · 2026-06-09 · Grant · Acquired 3,315 · Balance 866,474

F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.78 · Expires 2036-06-08Direct5,853 Reported balance After 2026-06-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-06-09 · Grant · Acquired 5,853 · Balance 5,853

F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.

SS Innovations International, Inc.

Report date March 06, 2026 · Filed March 10, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock, $0.0001 par valueSEC Table I · non-derivativeDirect10,775,485 Reported balance After 2026-03-06 transaction · row 1
1 source row

Row 1 · 2026-03-06 · Purchase · Acquired 501,253 · Balance 10,775,485

Venus Concept Inc.

Report date November 07, 2019 · Filed November 08, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect207,381 Reported balance After 2019-11-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2019-11-07 · Grant · Acquired 145,394 · Balance 207,381

F1: Received in connection with the Merger, upon the conversion of the outstanidng principal and any accrued and unpaid interest of two 8% Convertible Promissory Notes issued by Venus Concept Ltd., dated as of August 14, 2019 and August 21, 2019, in the original principal amounts of $197,142.85 and $802,857.15, respectively.

F2: Dr. Moll's previously reported holdings of common stock of the Issuer of 929,809 shares was adjusted to reflect the Issuer's 1-for-15 reverse stock split that occurred on November 7, 2019, which resulted in Dr. Moll's ownership of 867,822 less shares of common stock.

Common StockSEC Table I · non-derivativeDirect659,788 Reported balance After 2019-11-07 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2019-11-07 · Conversion · Acquired 452,407 · Balance 659,788

F3: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 6,432,246 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019.

F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019.

Common StockSEC Table I · non-derivativeDirect950,553 Reported balance After 2019-11-07 transaction · row 3 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 3 · 2019-11-07 · Conversion · Acquired 290,765 · Balance 950,553

F5: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 4,288,164 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019.

F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019.

Unsecured Subordinated Convertible Promissory NoteSEC Table II · derivative / convertible security · Expires 2020-08-28Direct0 Reported balance After 2019-11-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2019-11-07 · Conversion · Disposed Not disclosed · Balance 0

F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019.

F6: Through the date of conversion, the principal and interest under this Unsecured Subordinated Convertible Promissory Note, totaled $3,165,041.10 which total was converted into shares of common stock of the Issuer.

F7: This Unsecured Subordinated Convertible Promissory Note converted upon the consumation of the Merger, pursuant to its terms.

F3: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 6,432,246 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019.

Unsecured Subordinated Convertible Promissory NoteSEC Table II · derivative / convertible security · Expires 2020-08-28Direct0 Reported balance After 2019-11-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2019-11-07 · Conversion · Disposed Not disclosed · Balance 0

F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019.

F8: Through the date of conversion, the principal and interest under this Unsecured Subordinated Convertible Promissory Note, totaled $2,034,191.85 which total was converted into shares of common stock of the Issuer.

F7: This Unsecured Subordinated Convertible Promissory Note converted upon the consumation of the Merger, pursuant to its terms.

F5: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 4,288,164 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: Received in connection with the Merger, upon the conversion of the outstanidng principal and any accrued and unpaid interest of two 8% Convertible Promissory Notes issued by Venus Concept Ltd., dated as of August 14, 2019 and August 21, 2019, in the original principal amounts of $197,142.85 and $802,857.15, respectively.

F2: Dr. Moll's previously reported holdings of common stock of the Issuer of 929,809 shares was adjusted to reflect the Issuer's 1-for-15 reverse stock split that occurred on November 7, 2019, which resulted in Dr. Moll's ownership of 867,822 less shares of common stock.

F3: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 6,432,246 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019.

F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019.

F5: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 4,288,164 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019.

F6: Through the date of conversion, the principal and interest under this Unsecured Subordinated Convertible Promissory Note, totaled $3,165,041.10 which total was converted into shares of common stock of the Issuer.

F7: This Unsecured Subordinated Convertible Promissory Note converted upon the consumation of the Merger, pursuant to its terms.

F8: Through the date of conversion, the principal and interest under this Unsecured Subordinated Convertible Promissory Note, totaled $2,034,191.85 which total was converted into shares of common stock of the Issuer.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Shockwave Medical, Inc.

Report date May 31, 2024 · Filed May 31, 2024

Section 16 reporting ended · disclosed 2024-05-31. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2024-05-31 transaction · row 1
1 source row

Row 1 · 2024-05-31 · Disposition to issuer · Disposed 287,521 · Balance 0

F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),

F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2029-03-06Direct0 Reported balance After 2024-05-31 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2024-05-31 · Disposition to issuer · Disposed 17,381 · Balance 0

F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.20 · Expires 2025-06-16Direct0 Reported balance After 2024-05-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-05-31 · Disposition to issuer · Disposed 16,393 · Balance 0

F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),

F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.

F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 17, 2021 Filed Sep 21, 2021 22:34 UTC PROCEPT BioRobotics Corp PRCT · Entity 4831 ConversionCommon Stock 329,890 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-21-018954 · wf-form4_163226367108643.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 482,521

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock converted automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.

Read SEC document
June 28, 2021 Filed Jul 12, 2021 22:52 UTC Shockwave Medical, Inc. SWAV · Entity 90374 GrantCommon Stock 850 $0.00 $0.00
Disclosure

SEC source: 0000950103-21-010361 · dp154197_4-moll.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 279,429

F1 · shares: Reflects shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The shares subject to the restricted stock units vest on 6/25/2022, subject to the Reporting Person's continued service through such date.

Read SEC document
January 19, 2021 Filed Feb 5, 2021 18:53 UTC Intersect ENT, Inc. XENT · Entity 127294 Exercise / conversionStock Option (right to buy) · Derivative 12,500 $0.00 Strike: $0.72 $0.00
Disclosure

SEC source: 0001562180-21-000955 · primarydocument.xml · derivative · entry 2

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires 2021-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The vesting commencement date of the option is February 1, 2011. 7500 shares subject to the option vested on February 2, 2011 and 1/60th of the shares subject to the option vested monthly thereafter over 24 months.

Read SEC document
January 19, 2021 Filed Feb 5, 2021 18:53 UTC Intersect ENT, Inc. XENT · Entity 127294 Exercise / conversionCommon Stock 12,500 $0.72 $9,000.00
Disclosure

SEC source: 0001562180-21-000955 · primarydocument.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,961

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 5,011 restricted stock units.

Read SEC document
July 17, 2020 Filed Jul 22, 2020 00:36 UTC Shockwave Medical, Inc. SWAV · Entity 90374 GrantCommon Stock 2,701 $0.00 $0.00
Disclosure

SEC source: 0000950103-20-014014 · dp132624_4-moll.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,579

Read SEC document
June 04, 2020 Filed Jun 8, 2020 16:52 UTC Intersect ENT, Inc. XENT · Entity 127294 GrantStock Option (right to buy) · Derivative 9,666 $0.00 Strike: $11.84 $0.00
Disclosure

SEC source: 0001562180-20-004319 · primarydocument.xml · derivative · entry 2

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,666

Underlying: Common Stock · 9,666 shares

Expires 2030-06-03

F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2020.

Read SEC document
June 04, 2020 Filed Jun 8, 2020 16:52 UTC Intersect ENT, Inc. XENT · Entity 127294 GrantCommon Stock 5,011 $0.00 $0.00
Disclosure

SEC source: 0001562180-20-004319 · primarydocument.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 248,461

F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2021.

F2 · balance_after: Includes 5,011 restricted stock units.

Read SEC document
January 17, 2020 Filed Jan 22, 2020 17:02 UTC Intersect ENT, Inc. XENT · Entity 127294 GrantStock Option (right to buy) · Derivative 3,355 $0.00 Strike: $24.45 $0.00
Disclosure

SEC source: 0001562180-20-000477 · primarydocument.xml · derivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,355

Underlying: Common Stock · 3,355 shares

Expires 2030-01-16

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2020.

Read SEC document
November 07, 2019 Filed Nov 8, 2019 01:35 UTC Venus Concept Inc. VERO · Entity 55304 ConversionUnsecured Subordinated Convertible Promissory Note · Derivative Not disclosed $0.00 $2,000,000.00
Disclosure

SEC source: 0001382963-19-000115 · edgar.xml · derivative · entry 5

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 290,765 shares

Expires 2020-08-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019.

F8 · reported_value: Through the date of conversion, the principal and interest under this Unsecured Subordinated Convertible Promissory Note, totaled $2,034,191.85 which total was converted into shares of common stock of the Issuer.

F7 · derivative.exercise_date: This Unsecured Subordinated Convertible Promissory Note converted upon the consumation of the Merger, pursuant to its terms.

F5 · derivative.underlying_shares: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 4,288,164 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019.

Read SEC document
November 07, 2019 Filed Nov 8, 2019 01:35 UTC Venus Concept Inc. VERO · Entity 55304 ConversionUnsecured Subordinated Convertible Promissory Note · Derivative Not disclosed $0.00 $3,000,000.00
Disclosure

SEC source: 0001382963-19-000115 · edgar.xml · derivative · entry 4

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 452,407 shares

Expires 2020-08-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019.

F6 · reported_value: Through the date of conversion, the principal and interest under this Unsecured Subordinated Convertible Promissory Note, totaled $3,165,041.10 which total was converted into shares of common stock of the Issuer.

F7 · derivative.exercise_date: This Unsecured Subordinated Convertible Promissory Note converted upon the consumation of the Merger, pursuant to its terms.

F3 · derivative.underlying_shares: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 6,432,246 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019.

Read SEC document
November 07, 2019 Filed Nov 8, 2019 01:35 UTC Venus Concept Inc. VERO · Entity 55304 ConversionCommon Stock 290,765 Not disclosed Not disclosed
Disclosure

SEC source: 0001382963-19-000115 · edgar.xml · nonDerivative · entry 3

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 950,553

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · shares: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 4,288,164 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019.

F4 · price: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019.

Read SEC document
November 07, 2019 Filed Nov 8, 2019 01:35 UTC Venus Concept Inc. VERO · Entity 55304 ConversionCommon Stock 452,407 Not disclosed Not disclosed
Disclosure

SEC source: 0001382963-19-000115 · edgar.xml · nonDerivative · entry 2

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 659,788

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · shares: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 6,432,246 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019.

F4 · price: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019.

Read SEC document
November 07, 2019 Filed Nov 8, 2019 01:35 UTC Venus Concept Inc. VERO · Entity 55304 GrantCommon Stock 145,394 Not disclosed Not disclosed
Disclosure

SEC source: 0001382963-19-000115 · edgar.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,381

F1 · price: Received in connection with the Merger, upon the conversion of the outstanidng principal and any accrued and unpaid interest of two 8% Convertible Promissory Notes issued by Venus Concept Ltd., dated as of August 14, 2019 and August 21, 2019, in the original principal amounts of $197,142.85 and $802,857.15, respectively.

F2 · balance_after: Dr. Moll's previously reported holdings of common stock of the Issuer of 929,809 shares was adjusted to reflect the Issuer's 1-for-15 reverse stock split that occurred on November 7, 2019, which resulted in Dr. Moll's ownership of 867,822 less shares of common stock.

Read SEC document
October 07, 2019 Filed Oct 9, 2019 22:19 UTC Shockwave Medical, Inc. SWAV · Entity 90374 SaleCommon Stock 4,529 $31.93 $144,614.59
Disclosure

SEC source: 0000950103-19-013788 · dp114194_4-moll.xml · nonDerivative · entry 2

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,878

F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $31.82 to $32.21. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Read SEC document
October 07, 2019 Filed Oct 9, 2019 22:19 UTC Shockwave Medical, Inc. SWAV · Entity 90374 SaleCommon Stock 10,471 $31.49 $329,727.60
Disclosure

SEC source: 0000950103-19-013788 · dp114194_4-moll.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,407

F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 9/6/2019.

F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $30.82 to $31.81. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Read SEC document
August 20, 2019 Filed Aug 22, 2019 23:19 UTC Venus Concept Inc. HAIR · Entity 55304 PurchaseUnsecured Subordinated Convertible Promissory Note · Derivative Not disclosed $2,000,000.00 Strike: $0.47 $2,000,000.00
Disclosure

SEC source: 0001567619-19-017499 · doc1.xml · derivative · entry 2

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 4,288,164 shares

Expires 2020-08-28

F1 · derivative.exercise_date: The promissory note will convert upon the consummation of the transactions contemplated in that certain Agreement and Plan of Merger and Reorganization dated March 15, 2019, among the Issuer, Radiant Merger Sub Ltd., an entity organized under the laws of Israel and Venus Concept Ltd., an entity organized under the laws of Israel.

Read SEC document
August 20, 2019 Filed Aug 22, 2019 23:19 UTC Venus Concept Inc. HAIR · Entity 55304 PurchaseUnsecured Subordinated Convertible Promissory Note · Derivative Not disclosed $3,000,000.00 Strike: $0.47 $3,000,000.00
Disclosure

SEC source: 0001567619-19-017499 · doc1.xml · derivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: Not disclosed

Underlying: Common Stock · 6,432,246 shares

Expires 2020-08-28

F1 · derivative.exercise_date: The promissory note will convert upon the consummation of the transactions contemplated in that certain Agreement and Plan of Merger and Reorganization dated March 15, 2019, among the Issuer, Radiant Merger Sub Ltd., an entity organized under the laws of Israel and Venus Concept Ltd., an entity organized under the laws of Israel.

Read SEC document
June 04, 2019 Filed Jun 6, 2019 18:10 UTC Intersect ENT, Inc. XENT · Entity 127294 GrantStock Option (right to buy) · Derivative 5,172 $0.00 Strike: $23.02 $0.00
Disclosure

SEC source: 0001562180-19-003399 · primarydocument.xml · derivative · entry 2

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,172

Underlying: Common Stock · 5,172 shares

Expires 2029-06-03

F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2019.

Read SEC document
June 04, 2019 Filed Jun 6, 2019 18:10 UTC Intersect ENT, Inc. XENT · Entity 127294 GrantCommon Stock 2,312 $0.00 $0.00
Disclosure

SEC source: 0001562180-19-003399 · primarydocument.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 243,450

F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2020.

F2 · balance_after: Includes 2,312 restricted stock units.

Read SEC document
March 11, 2019 Filed Mar 13, 2019 20:29 UTC Shockwave Medical, Inc. SWAV · Entity 90374 ConversionSeries C Convertible Preferred Stock · Derivative 24,347 Not disclosed Not disclosed
Disclosure

SEC source: 0000950103-19-003372 · dp103686_4-moll.xml · derivative · entry 8

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,347 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

F1 · derivative.exercise_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

Read SEC document
March 11, 2019 Filed Mar 13, 2019 20:29 UTC Shockwave Medical, Inc. SWAV · Entity 90374 ConversionSeries B Convertible Preferred Stock · Derivative 28,767 Not disclosed Not disclosed
Disclosure

SEC source: 0000950103-19-003372 · dp103686_4-moll.xml · derivative · entry 7

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,767 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

F1 · derivative.exercise_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

Read SEC document
March 11, 2019 Filed Mar 13, 2019 20:29 UTC Shockwave Medical, Inc. SWAV · Entity 90374 ConversionSeries A-1 Convertible Preferred Stock · Derivative 114,107 Not disclosed Not disclosed
Disclosure

SEC source: 0000950103-19-003372 · dp103686_4-moll.xml · derivative · entry 6

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 114,107 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

F1 · derivative.exercise_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

Read SEC document
March 11, 2019 Filed Mar 13, 2019 20:29 UTC Shockwave Medical, Inc. SWAV · Entity 90374 ConversionSeries A Convertible Preferred Stock · Derivative 123,657 Not disclosed Not disclosed
Disclosure

SEC source: 0000950103-19-003372 · dp103686_4-moll.xml · derivative · entry 5

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 123,657 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

F1 · derivative.exercise_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

F1 · derivative.expiration_date: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

Read SEC document
March 11, 2019 Filed Mar 13, 2019 20:29 UTC Shockwave Medical, Inc. SWAV · Entity 90374 ConversionCommon Stock 24,347 Not disclosed Not disclosed
Disclosure

SEC source: 0000950103-19-003372 · dp103686_4-moll.xml · nonDerivative · entry 4

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 290,878

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

Read SEC document
March 11, 2019 Filed Mar 13, 2019 20:29 UTC Shockwave Medical, Inc. SWAV · Entity 90374 ConversionCommon Stock 28,767 Not disclosed Not disclosed
Disclosure

SEC source: 0000950103-19-003372 · dp103686_4-moll.xml · nonDerivative · entry 3

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 266,531

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

Read SEC document
March 11, 2019 Filed Mar 13, 2019 20:29 UTC Shockwave Medical, Inc. SWAV · Entity 90374 ConversionCommon Stock 114,107 Not disclosed Not disclosed
Disclosure

SEC source: 0000950103-19-003372 · dp103686_4-moll.xml · nonDerivative · entry 2

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,764

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

Read SEC document
March 11, 2019 Filed Mar 13, 2019 20:29 UTC Shockwave Medical, Inc. SWAV · Entity 90374 ConversionCommon Stock 123,657 Not disclosed Not disclosed
Disclosure

SEC source: 0000950103-19-003372 · dp103686_4-moll.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,657

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share the convertible preferred stock automatically converted into shares of Common Stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering without payment or consideration. The shares of the convertible preferred stock had no expiration date.

Read SEC document
March 06, 2019 Filed Mar 8, 2019 21:45 UTC Shockwave Medical, Inc. SWAV · Entity 90374 GrantStock Options (Right to Buy) · Derivative 17,381 $0.00 Strike: $17.00 $0.00
Disclosure

SEC source: 0000950103-19-003227 · dp103551_4-moll.xml · derivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,381

Underlying: Common Stock · 17,381 shares

Expires 2029-03-06

F1 · derivative.exercise_date: 1/3rd of the options shall vest each year beginning on March 11, 2020 until 100% of the options have vested.

Read SEC document
January 16, 2019 Filed Jan 18, 2019 17:36 UTC Intersect ENT, Inc. XENT · Entity 127294 GrantStock Option (right to buy) · Derivative 3,220 $0.00 Strike: $28.58 $0.00
Disclosure

SEC source: 0001562180-19-000369 · primarydocument.xml · derivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,220

Underlying: Common Stock · 3,220 shares

Expires 2029-01-15

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2019.

Read SEC document
August 09, 2018 Filed Aug 13, 2018 22:18 UTC Venus Concept Inc. HAIR · Entity 55304 PurchaseCommon Stock 333,333 $1.50 $499,999.50
Disclosure

SEC source: 0001567619-18-000663 · doc1.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 929,809

F1 · kind: The shares were acquired in connection with an underwritten public offering of common stock which closed on August 14, 2018.

Read SEC document
June 13, 2018 Filed Jun 15, 2018 20:07 UTC Venus Concept Inc. HAIR · Entity 55304 GrantStock Option (Right to Buy) · Derivative 13,708 $0.00 Strike: $2.89 $0.00
Disclosure

SEC source: 0000899243-18-016757 · doc4.xml · derivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,708

Underlying: Common Stock · 13,708 shares

Expires 2028-06-13

F1 · derivative.exercise_date: The option will vest in full on the earlier of (A) June 13, 2019 or (B) immediately prior to the next annual meeting of the Company's stockholders, subject to continued service on the board of directors through each applicable vesting date.

Read SEC document
June 05, 2018 Filed Jun 7, 2018 17:20 UTC Intersect ENT, Inc. XENT · Entity 127294 GrantStock Options (Right to buy) · Derivative 3,473 $0.00 Strike: $42.05 $0.00
Disclosure

SEC source: 0001562180-18-002918 · primarydocument.xml · derivative · entry 2

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,473

Underlying: Common Stock · 3,473 shares

Expires 2028-06-04

F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 5, 2018.

Read SEC document
June 05, 2018 Filed Jun 7, 2018 17:20 UTC Intersect ENT, Inc. XENT · Entity 127294 GrantCommon Stock 1,514 $0.00 $0.00
Disclosure

SEC source: 0001562180-18-002918 · primarydocument.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241,138

F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 5, 2019.

F2 · balance_after: Includes 1,514 RSUs.

Read SEC document
January 17, 2018 Filed Jan 19, 2018 17:17 UTC Intersect ENT, Inc. XENT · Entity 127294 GrantStock Options (Right to buy) · Derivative 2,797 $0.00 Strike: $33.95 $0.00
Disclosure

SEC source: 0001562180-18-000369 · primarydocument.xml · derivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,797

Underlying: Common Stock · 2,797 shares

Expires 2028-01-16

F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2018.

Read SEC document
November 20, 2017 Filed Nov 20, 2017 17:37 UTC Intersect ENT, Inc. XENT · Entity 127294 SaleCommon Stock 2,500 $28.76 $71,895.00
Disclosure

SEC source: 0001562180-17-003642 · primarydocument.xml · nonDerivative · entry 3

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 239,624

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.75 to $28.80, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4.

Read SEC document
November 17, 2017 Filed Nov 20, 2017 17:37 UTC Intersect ENT, Inc. XENT · Entity 127294 SaleCommon Stock 5,000 $28.74 $143,707.50
Disclosure

SEC source: 0001562180-17-003642 · primarydocument.xml · nonDerivative · entry 2

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,124

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.60 to $28.90, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4.

Read SEC document
November 16, 2017 Filed Nov 20, 2017 17:37 UTC Intersect ENT, Inc. XENT · Entity 127294 SaleCommon Stock 6,700 $28.77 $192,763.69
Disclosure

SEC source: 0001562180-17-003642 · primarydocument.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,124

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $29.05, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4.

Read SEC document
November 10, 2017 Filed Nov 14, 2017 18:01 UTC Intersect ENT, Inc. XENT · Entity 127294 SaleCommon Stock 800 $29.00 $23,200.00
Disclosure

SEC source: 0001562180-17-003559 · primarydocument.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,824

Read SEC document
October 16, 2017 Filed Oct 17, 2017 22:37 UTC Venus Concept Inc. HAIR · Entity 55304 ConversionSeries C Preferred Stock · Derivative 46,620 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-17-038915 · doc1.xml · derivative · entry 6

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 46,620 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering.

F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering.

F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering.

F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities.

Read SEC document
October 16, 2017 Filed Oct 17, 2017 22:37 UTC Venus Concept Inc. HAIR · Entity 55304 ConversionSeries B Preferred Stock · Derivative 153,846 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-17-038915 · doc1.xml · derivative · entry 5

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 153,846 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering.

F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering.

F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering.

F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities.

Read SEC document
October 16, 2017 Filed Oct 17, 2017 22:37 UTC Venus Concept Inc. HAIR · Entity 55304 ConversionSeries A Preferred Stock · Derivative 316,725 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-17-038915 · doc1.xml · derivative · entry 4

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 316,725 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering.

F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering.

F1 · derivative.exercise_date: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering.

F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities.

Read SEC document
October 16, 2017 Filed Oct 17, 2017 22:37 UTC Venus Concept Inc. HAIR · Entity 55304 ConversionCommon Stock 46,620 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-17-038915 · doc1.xml · nonDerivative · entry 3

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 596,476

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering.

Read SEC document
October 16, 2017 Filed Oct 17, 2017 22:37 UTC Venus Concept Inc. HAIR · Entity 55304 ConversionCommon Stock 153,846 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-17-038915 · doc1.xml · nonDerivative · entry 2

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 549,856

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering.

Read SEC document
October 16, 2017 Filed Oct 17, 2017 22:37 UTC Venus Concept Inc. HAIR · Entity 55304 ConversionCommon Stock 316,725 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-17-038915 · doc1.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 396,010

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering.

Read SEC document
June 30, 2017 Filed Jul 3, 2017 17:48 UTC BIOLASE, INC BIOL · Entity 11470 ConversionSeries D Participating Convertible Preferred Stock · Derivative 1,921 $0.00 Strike: $1.24 $0.00
Disclosure

SEC source: 0001209191-17-042884 · doc4.xml · derivative · entry 2

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 192,100 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: These shares of Series D Participating Convertible Preferred Stock ("Preferred Stock") were acquired by Frederic H. Moll in a private placement with the Issuer, which closed on April 18, 2017.

F3 · derivative.expiration_date: The Preferred Stock had no expiration date.

Read SEC document
June 30, 2017 Filed Jul 3, 2017 17:48 UTC BIOLASE, INC BIOL · Entity 11470 ConversionCommon Stock 192,100 $1.24 $238,204.00
Disclosure

SEC source: 0001209191-17-042884 · doc4.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 251,317

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On June 30, 2017, as a result of receipt of the Requisite Stockholder Approval (defined and described further in the Securities Purchase Agreement dated April 11, 2017 and filed as Exhibit 99.1 to the Current Report on Form 8-K filed by the Issuer on April 14, 2017), each share of Preferred Stock (as defined below) automatically converted into 100 shares of Common Stock, reflecting a conversion price equal to $1.24 per share.

Read SEC document
June 01, 2017 Filed Jun 5, 2017 19:29 UTC Intersect ENT, Inc. XENT · Entity 127294 GrantStock Options (Right to buy) · Derivative 6,035 $0.00 Strike: $26.05 $0.00
Disclosure

SEC source: 0001562180-17-002199 · primarydocument.xml · derivative · entry 2

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,035

Underlying: Common Stock · 6,035 shares

Expires 2027-05-31

F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 1, 2017.

Read SEC document
June 01, 2017 Filed Jun 5, 2017 19:29 UTC Intersect ENT, Inc. XENT · Entity 127294 GrantCommon Stock 2,546 $0.00 $0.00
Disclosure

SEC source: 0001562180-17-002199 · primarydocument.xml · nonDerivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 254,624

F1 · security: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 1, 2018.

Read SEC document
May 10, 2017 Filed May 12, 2017 16:10 UTC BIOLASE, INC BIOL · Entity 11470 GrantRestricted Stock Unit · Derivative 35,211 $0.00 $0.00
Disclosure

SEC source: 0001209191-17-031900 · doc4.xml · derivative · entry 2

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,211

Underlying: Common Stock · 35,211 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock.

F3 · derivative.exercise_date: The restricted stock unit award fully vests and is immediately exercisable on the first anniversary of the date of the award.

F3 · derivative.expiration_date: The restricted stock unit award fully vests and is immediately exercisable on the first anniversary of the date of the award.

Read SEC document
May 10, 2017 Filed May 12, 2017 16:10 UTC BIOLASE, INC BIOL · Entity 11470 GrantStock Option (right to buy) · Derivative 105,634 $0.00 Strike: $1.21 $0.00
Disclosure

SEC source: 0001209191-17-031900 · doc4.xml · derivative · entry 1

MOLL FREDERIC H · CIK 0001260157 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 456,623

Underlying: Common Stock · 105,634 shares

Expires 2027-05-10

F1 · derivative.exercise_date: The stock option vests and is exercisable in equal monthly installments over a consecutive 12-month period, commencing one month from the date of grant.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.